Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8478461 | Molecular and Cellular Neuroscience | 2016 | 8 Pages |
Abstract
Moreover, our current study established for the first time that NB-DNJ, a drug already used as a therapeutic for Gaucher disease (a lysosomal storage disorder), was also able to reduce Aβ production in our cellular model. Therefore, our study provides novel information regarding the possibilities to target amyloidogenic processing of APP through modulation of sphingolipid metabolism and emphasizes the potential of the iminosugar NB-DNJ as a disease modifying therapy for AD.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cell Biology
Authors
Anastasia Noel, Sabrina Ingrand, Laurence Barrier,